SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT) is gaining traction as a 'move-to-earn' cryptocurrency, sparking community discussion around its utility in rewarding physical activity with digital assets, while investors keenly anticipate a future price recovery amidst its historically low valuation.

Forum Energy Technologies, Inc. designs, manufactures, and distributes products to the oil and natural gas industry. It operates through the Drilling and Completions and Artificial Lift and Downhole segments. The Drilling and Completions segment designs, manufactures and supplies products and solutions to the drilling, subsea, coiled tubing, well stimulation and intervention markets, including applications in oil and natural gas, renewable energy, defense and communications. The Artificial Lift and Downhole segment designs, manufactures and supplies products and solutions for the artificial lift, production and infrastructure markets. The company was founded in 2005 and is headquartered in Houston, TX.

Forum Energy Technologies Inc

Forum Energy Technologies (FET) is trending as recent financial results and an ambitious "FET 2030" plan reinforce strong long-term growth and value creation potential. The community is actively discussing the company's solid execution, robust free cash flow, and strategic debt reduction and buybacks, seeing it as significantly undervalued at the bottom of the cyclical oilfield services market.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares (LABU) is trending amid surging interest in the biotech sector, driven by ongoing advancements and significant investment in AI-driven drug discovery. The community is actively discussing a robust rally, with expectations for continued growth fueled by strategic collaborations and M&A activity within innovative healthcare.

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Okta is seeing renewed interest driven by its recent $1 billion share buyback authorization and a wave of analyst upgrades, leading the community to view it as undervalued. Conversations highlight the company's strong earnings and its strategic positioning to capitalize on securing AI agents, which many believe presents a significant future growth opportunity.

ASE Technology Holding Co., Ltd. engages in the provision of semiconductor manufacturing services. It develops and offers complete turnkey solutions in IC (Integrated Circuit) packaging, design and production of interconnect materials, front-end engineering testing, wafer probing and final testing, as well as electronic manufacturing services. The company was founded on April 30, 2018 and is headquartered in Kaohsiung City, Taiwan.

ASE Technology Holding Co.Ltd - ADR

Advanced Semiconductor Engineering Inc.

ASX is trending due to strong earnings and revenue beats, coupled with significant expansion in its semiconductor packaging and testing capabilities critical for AI. The community is highly bullish, viewing it as an undervalued AI growth play and a key supplier for industry leaders like NVIDIA amidst the ongoing AI data center buildout.

American Superconductor Corp. engages in the provision of megawatt-scale power solutions. Its products include electric control systems, generators & drivetrains, power converters, renewable interconnectivity solutions, software, turbine designs, utility and industrial resilience and modernization solutions, and utility voltage solutions. It operates through the Grid and Wind segments. The Grid segment enables electric utilities and renewable energy project developers to connect, transmit, and distribute power with efficiency, reliability, security, and affordability. The Wind segment permits the manufacturers to field wind turbines with power output, reliability, and affordability. The company was founded by Yet Ming Chiang, David A. Rudman, John B. Vander Sande, and Gregory J. Yurek on April 9, 1987 and is headquartered in Ayer, MA.

American Superconductor Corp.

American Superconductor is seeing heightened interest following a robust earnings report and optimistic guidance, driving community focus on its essential contributions to modernizing power grids for AI data centers and growing defense sector engagements.

Vail Resorts, Inc. is a holding company, which engages in the operation of mountain resorts. It operates through the following segments: Mountain, Lodging, and Real Estate. The Mountain segment covers the operation of mountain resorts or ski areas, and related activities. The Lodging segment includes ownership of hotels, RockResorts, NPS concessionaire properties, condominium management, Colorado resort ground transportation operations, and mountain resort golf operations. The Real Estate segment owns, develops, and sells real estate in and around its resort communities. The company was founded by Pete Seibert and Earl Eaton in March 1957 and is headquartered in Broomfield, CO.

Vail Resorts Inc.

Vail Resorts is trending after recent earnings revealed missed revenue targets and lowered guidance, primarily due to poor snowfall across North American resorts and ongoing criticism regarding customer experience and operational issues like understaffing. While many in the community express frustration over the company's "broken business model" and a perceived decline in service, news of former CEO Rob Katz returning has provided a contrasting surge of optimism and analyst upgrades.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending amid a notable price bounce, propelled by its strategic advancements in AI integration, including an NVIDIA partnership, and the expanding utility of its NEAR Intents for seamless cross-chain interoperability. The community is also actively discussing its remarkable user growth, which has reportedly surpassed major blockchains.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind (MNKD) is trending with investors focused on its imminent earnings report and CEO presentation, alongside strong anticipation for multiple near-term FDA approvals for pediatric Afrezza and the Furoscix autoinjector, which divide community sentiment between high growth expectations and concerns over past commercialization and executive leadership.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is trending due to its robust community-led narrative as the "third frog" in the Matt Furie universe, directly representing Pepe and promising significant upside as a beta play in the frog memecoin meta. Despite broader market downturns, its dedicated community is actively building and highlighting the token's resilience and strong ties to established meme lore on the Ethereum network.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average - Here's Why

Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200 Day Moving Average - Time to Sell...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat Ratings reports. One...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the firm, MarketBeat Ratings reports. One...

Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher - Here's What Happened

Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher - Here's What Happened...

Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB

Ellsworth Advisors LLC bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) during the third quarter, according to the company in its most recent 13F filing with the...

Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6% - What's Next?

Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6% - Should You Sell...

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

<ul class="summary-bullets"><li>Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option.</li><li>H.C. Wainwright believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."</li><li>According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes.</li></ul>Shares of Assembly Biosciences Inc closed up 3% on Monday after Gilead Sciences exercised the option to license the company’s programs for recurrent genital herpes in a move applauded by Wall Street. &nbsp;The programs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gilead.com/news/news-details/2025/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes"> include</a> investigational candidates ABI-1179 and ABI-5366. Gilead will advance the clinical development and commercialization of the programs under its ongoing collaboration with Assembly Bio which was inked in 2023 and spans 12 years. Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option and remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.H.C. Wainwright analyst Patrick Trucchio subsequently reiterated a ‘Buy’ rating on Assembly Biosciences (ASMB) with a $50 price target. The analyst believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."<h2 class="st-heading-2">About The Programs</h2>Genital herpes is a common sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), leading to painful blisters and sores around the genitals or anus, though many people have mild or no symptoms and don't know they're infected. Spread through skin-to-skin contact, especially during sex, the virus stays in the body, causing recurring outbreaks triggered by stress, illness, or fatigue.According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes. No new therapies have been approved for HSV in the U.S. or Europe for more than 25 years, the company noted.ABI-1179 and ABI-5366 are novel long-acting inhibitors of viral helicase-primase, an enzyme essential for herpes virus replication. Positive interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated strong antiviral activity and improvements in clinical outcomes, including significant reduction in virus-positive lesions, the company noted. Both compounds also exhibit pharmacokinetic and safety profiles supportive of once-weekly oral dosing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/ASMB"> ASMB </a>rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.Sentiment around GILD stayed within the 'neutral' territory in the meantime.<a href="https://stocktwits.com/symbol/GILD">Shares of GILD</a> have risen nearly 34% this year while ASMB shares have more than doubled.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-rival-ula-ceo-tory-bruno-steps-down/cLeFtcyREub">SpaceX Rival ULA CEO Tory Bruno Steps Down After 12 Years — Says ‘My Work Here Is Now Complete’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.

Equity

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.


Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - Should You Buy?

Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - What's Next...

Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Monday...

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Current Price	$28.75
Prev Close	$25.97
Open	$26.03
Dividend Yield	0.00%
50-Day Moving Average	$30.27
Beta	1.13
Avg. Volume	108,113.25
PE Ratio	-5.99

52-Week High	$39.71
52-Week Low	$7.75
Market Capitalization	$454.74M
EPS (Annual)	-$6.69
Price to Book	2.49
Revenue Per Employee	$390,684.93

ASMB
Assembly Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ASMB News

ASMBAssembly Biosciences Inc